You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Dovato

Product menu

NA NA

An innovative treatment for your patients living with HIV

Bar chart image
Powerful, Durable Efficacy1,2
HBR shield image
High Barrier to Resistance1
Pill bottle image
TDF, TAF and ABC Free1

Dovato is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.3

Proven efficacy in real-world studies and clinical trials across a broad range of >45,000 people living with HIV4,5,6,7,8

SEE THE DATA

Document icon

Explore Dovato Resources

View insightful webinars, order patient resources, download infographics, and more.

Explore Resources
Positive perspective circle image

What Matters Most to People Living With HIV?

See Positive Perspective data on factors associated with improved quality-of-life outcomes

VIEW THE STUDY
HBR shield image

What Data Supports the High Barrier to Resistance of Dovato?

Explore results from clinical trials and real-world studies

Learn more on Resistance

RECOMMENDED IN TREATMENT GUIDELINES

Dovato is recommended by the EACS, DHHS and IAS for people living with HIV.9-11

Review the Guidelines

POM. Further information available from GlaxoSmithKline, 12 Riverwalk, Citywest, Business Campus, Dublin 24. Tel: 01-4955000.

References:

  1. Cahn P, Sierra Madero J, Arribas JR, et al. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-navie adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. J Acquired Immune Defic Syndr. 2020;83(3):310-318.
  2. Van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: Phase 3, randomised noninferioity TANGO study. Clin Infect Dis. 2020. doi:10.1093/cid/ciz1243.
  3. Dovato Summary of Product Characteristics. Available at: https://www.medicines.ie/medicines/dovato-50-mg-300-mg-film-coated-tablets-34871/smpc. Last Accessed November 2025.
  4. Cahn P et al. AIDS 2022; 36(1): 39–48
  5. De Wit S et. J Acquir Immune Defic Syndr 2024. 96(2): 156—160.
  6. Rolle C et al. Open Forum Infect Dis 2023; 10(3): 1–9.
  7. Llibre J et al. Clin Infect Dis 2023; 76(4): 720–729.
  8. ViiV Healthcare. Data on File. REF-237004. 2024
  9. European AIDS Clinical Society Guidelines version 12.0, October 2023. Accessed November 2025. Available at: https://www.eacsociety.org/media/guidelines-12.0.pdf
  10. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Last Accessed November 2025. Updated: September 21, 2022. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf
  11. Gandhi RT, Landovitz RJ, Sax PE, et al. Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel. JAMA. Published online December 1, 2024. doi:https://doi.org/10.1001/jama.2024.24543

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie.
Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via online form https://gsk.public.reportum.com/.

Dovato is a registered trade mark of the ViiV Healthcare group of companies or its licensor.

Date of preparation: November 2025 | PM-IE-DLL-WCNT-250007